Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBD104409
- Development stage
- Phase 1
- Lead developer
- Baiguo Yukang Information Service
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KBD104409 (also known as KBD4409) is an orally bioavailable small molecule inhibitor of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8), developed by Kangbaida (a wholly-owned subsidiary of Chengdu Baiyu Pharmaceutical) in collaboration with Sichuan Hongmingbosi Pharmaceutical. It selectively targets TLR7 and TLR8 without significant inhibition of TLR4 or TLR9. KBD104409 is being developed for the treatment of autoimmune diseases, specifically systemic lupus erythematosus (SLE). In preclinical models of SLE, the drug demonstrated significant efficacy, including prolonged survival, improved proteinuria, and reduced autoantibody levels. It is currently in Phase 1 clinical development in China.
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on KBD104409.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBD104409.